Literature DB >> 22286051

Hypoxia-ischemia upregulates TRAIL and TRAIL receptors in the immature rat brain.

Zhiheng Huang1, Lili Song, Congmin Wang, Jiang-Qin Liu, Chao Chen.   

Abstract

The immature brain is susceptible to inflammatory injury induced by hypoxia-ischemia (HI) or infection, which causes serious neurodevelopmental disabilities in the survivors of preterm births. Recently, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors (death receptor DR4/5 and decoy receptor DcR1/2) were reported to mediate various neuroinflammatory responses. However, little information is available regarding the role of TRAIL and its receptors in the immature brain after HI. The purpose of this study was to evaluate the expression of TRAIL and its receptors in the immature brain after HI and relate this expression to neurological function. We performed right common carotid artery ligation followed by hypoxia (6% O(2), 37°C) for 2.5 h to induce HI in postnatal day 3 rats. The distribution of TRAIL and its receptors, caspase-3 and CD68-labeled microglia/macrophages was evaluated 24 h after HI by immunostaining. The protein and mRNA expression of TRAIL and DR5 was measured by Western blot and real-time PCR, respectively. Delayed neuronal loss was evaluated by NeuN and Nissl staining 7 days after HI. Furthermore, neurological deficits were evaluated by a righting reflex test, time of eye opening and T-maze test. The expression of TRAIL, DR5 and DcR1/2 receptors and caspase-3 was more pronounced in the ipsilateral hemisphere compared with the contralateral part and the control group 24 h after HI. DR5/active caspase-3 double-positive cells were observed at 24 h after HI in the ipsilateral hemisphere but not in the contralateral hemisphere. The TRAIL and CD68 double-labeled cells were more pronounced in the ipsilateral cortical regions compared with the corresponding regions of the contralateral part. HI also resulted in a significant increase in TRAIL and DR5 protein and mRNA expression at 24 h, which corresponded to neuronal cell loss 7 days after HI. Furthermore, the HI group displayed impaired neurobehavioral development compared with the control group (p < 0.05). Altogether our results show that the TNF-α superfamily ligand TRAIL is induced on CD68+ microglia/macrophages after perinatal HI and that one of its receptors, DR5, is induced on neocortical neurons and glial cells. That many DR5+ cells were also caspase-3+ strongly supports the conclusion that these signaling molecules are involved in the delayed loss of neurons in the neocortex and in the neurobehavioral deficits that are often seen after perinatal HI.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286051     DOI: 10.1159/000334475

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  11 in total

Review 1.  Pathophysiology and neuroprotection of global and focal perinatal brain injury: lessons from animal models.

Authors:  Luigi Titomanlio; David Fernández-López; Lucilla Manganozzi; Raffaella Moretti; Zinaida S Vexler; Pierre Gressens
Journal:  Pediatr Neurol       Date:  2015-01-31       Impact factor: 3.372

2.  Tissue Injury and Astrocytic Reaction, But Not Cognitive Deficits, Are Dependent on Hypoxia Duration in Very Immature Rats Undergoing Neonatal Hypoxia-Ischemia.

Authors:  L E Durán-Carabali; E F Sanches; F K Odorcyk; F Nicola; R G Mestriner; L Reichert; D Aristimunha; A S Pagnussat; C A Netto
Journal:  Neurochem Res       Date:  2019-09-28       Impact factor: 3.996

3.  Remote Limb Preconditioning Generates a Neuroprotective Effect by Modulating the Extrinsic Apoptotic Pathway and TRAIL-Receptors Expression.

Authors:  Wei Xu; Wei Jin; Xiaoxiao Zhang; Jing Chen; Chuancheng Ren
Journal:  Cell Mol Neurobiol       Date:  2016-03-14       Impact factor: 5.046

4.  Molecular features of neural stem cells enable their enrichment using pharmacological inhibitors of survival-promoting kinases.

Authors:  Christine Y Brazel; Abdulaziz A Alaythan; Ryan J Felling; Frances Calderon; Steven W Levison
Journal:  J Neurochem       Date:  2013-10-10       Impact factor: 5.372

5.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling and cell death in the immature central nervous system after hypoxia-ischemia and inflammation.

Authors:  Anton Kichev; Catherine I Rousset; Ana A Baburamani; Steven W Levison; Teresa L Wood; Pierre Gressens; Claire Thornton; Henrik Hagberg
Journal:  J Biol Chem       Date:  2014-02-07       Impact factor: 5.157

Review 6.  Clinical perspectives of TRAIL: insights into central nervous system disorders.

Authors:  Veronica Tisato; Arianna Gonelli; Rebecca Voltan; Paola Secchiero; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2016-02-24       Impact factor: 9.261

7.  Thioperamide treats neonatal hypoxic-ischemic encephalopathy by postsynaptic H1 receptors.

Authors:  Feiyong Jia; Lin Du; Yunpeng Hao; Shicheng Liu; Ning Li; Huiyi Jiang
Journal:  Neural Regen Res       Date:  2013-07-05       Impact factor: 5.135

8.  Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype.

Authors:  G Cantarella; G Pignataro; G Di Benedetto; S Anzilotti; A Vinciguerra; O Cuomo; G F Di Renzo; C Parenti; L Annunziato; R Bernardini
Journal:  Cell Death Dis       Date:  2014-07-17       Impact factor: 8.469

9.  Follow-up Analysis of Serum TNF-Related Apoptosis-Inducing Ligand Protein and mRNA Expression in Peripheral Blood Mononuclear Cells from Patients with Ischemic Stroke.

Authors:  Kemal Ugur Tufekci; Ufuk Vurgun; Onur Yigitaslan; Pembe Keskinoglu; Erdem Yaka; Kursad Kutluk; Sermin Genc
Journal:  Front Neurol       Date:  2018-03-05       Impact factor: 4.003

10.  Effects of Hypoxia and Bed Rest on Markers of Cardiometabolic Risk: Compensatory Changes in Circulating TRAIL and Glutathione Redox Capacity.

Authors:  Gianni Biolo; Filippo G Di Girolamo; Adam McDonnell; Nicola Fiotti; Filippo Mearelli; Roberta Situlin; Arianna Gonelli; Barbara Dapas; Mauro Giordano; Mitja Lainscak; Gabriele Grassi; Giorgio Zauli; Paola Secchiero; Igor Mekjavic
Journal:  Front Physiol       Date:  2018-07-30       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.